Background: Human papillomavirus (HPV) is a known causative factor in the etiology of cervical cancer. Methods: HPV DNA genotyping was performed in menstrual blood (MB) collected in napkins from patients with cervical intraepithelial neoplasia (CIN), HPV infection and sexually active apparently normal subjects. In the same patient cohort, MB TAP1 I333V and TAP1 D637G gene polymorphisms were examined.
Cervical cancer (CC) is the second most common cancer and cause of cancer-related death in women worldwide [1, 2] . The well-defined premalignant phase of this cancer has contributed to the success of the cytology-based Papanicolaou (Pap) screening test, through which the incidence of CC in resource-rich countries has been dramatically reduced [3, 4] . However, the Pap test has several limitations: (1) cervical cell collection by this method may cause pain and embarrassment [5] [6] [7] , (2) the subjective assessment of results makes the test highly susceptible to intraindividual and interindividual variability [4] , (3) its sensitivity in detecting CC is low, at about 51% [3, 4] , and (4) it requires cytology-trained personnel and special equipment with stringent quality control, which involves a huge amount of resources [8, 9] . Therefore, there is a need for another cervical screening test that can overcome these limitations.
Recent studies have shown that the human papillomavirus (HPV) DNA test is useful for CC screening, especially in low-resource countries [10] [11] [12] . Although it has a much higher sensitivity than the Pap test in detecting high-grade cervical intraepithelial neoplasia (HGCIN), its specificity is comparatively lower [3] . Moreover, the HPV DNA test is still invasive, involving possible pain and embarrassment. In a previous study, Wong et al [13] demonstrated that menstrual blood (MB) HPV DNA is a potential noninvasive marker for these premalignant cervical diseases. Therefore, in the first part of the current study, HPV DNA was detected in patients with various clinical stages of premalignant cervical diseases to explore whether MB HPV DNA can be used to monitor patients with high-risk (HR) HPV for relapse.
A series of events must take place for effective antigen presentation to occur so that the cytotoxic T cells can kill the HPVinfected cell. The transporter associated with antigen processing (TAP) is responsible for assembling class I major histocompatibility complex (MHC-I) proteins in the endoplasmic reticulum [14] . Moreover, TAP proteins facilitate the HPV peptides to enter into the rough endoplasmic reticulum so that these peptides can be complexed with MHC-I molecules for killing by cytotoxic T cells [15] . However, HPV can evade immune detection by decreasing MHC-I expression on HPV-infected cells through down-regulation of TAP1 levels [16] . Recently, TAP1 I333V and TAP1 D637G gene polymorphisms have been used to identify women at less risk of progression to HGCIN and CC [17] .
These gene polymorphisms can protect against immune evasion despite the oncogenicity of HPV type by affecting the messenger RNA or protein products so they become more resistant to degradation or by eliciting an early cell-mediated immune response against HPV [17] . Therefore, in the second part of the current study, we hypothesized that both TAP1 gene polymorphisms could be detected in the MB from the same cohort of patients and that they were significantly associated with a protective effect for development of HGCIN. The information obtained would be very important for our understanding of whether MB TAP1 gene polymorphisms can be used to triage subjects with HPV-positive MB by predicting HGCIN risk.
Because MB collected in a napkin is usually treated as garbage to be disposed in a litter bin rather than being kept for a laboratory test, it is important to know to what extent women would accept the use of MB collected in a napkin as a clinical specimen for an HPV DNA test. In fact, this use MB cannot be implemented without women's acceptance, even if the test is confirmed to be useful. To determine women's acceptance of using MB for HPV DNA testing, a set of questions was specially designed and sent to 5000 women of different age groups, marital status, educational background, and occupations.
METHODS

Study Population
Two hundred sixty-five patients with pathological diagnosis of CIN3, CIN2, CIN1 or HPV infection were recruited in the Department of Obstetrics & Gynaecology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region. Within this cohort, 118 patients with CIN3 or CIN2 underwent loop electrosurgical excision procedures, and 76 with CIN1 or HPV infection with recovery to normal, as proved by Pap test, were also recruited for HPV DNA detection. In addition, 137 sexually active apparently normal subjects (ANSs), with no history of cervical disease, were recruited as controls.
Study Procedures
All participants were subjected to a short interview, including a brief introduction to this study and questions concerning their medical, gynecological, and sexual history. ANSs with positive MB HPV DNA results were referred for Pap test and colposcopy with histological confirmation.
Laboratory Analysis
MB collected on napkins was put inside zippered plastic bags, which were sent to the laboratory by mail or by hand. A small piece of napkin was cut out (1 cm × 1 cm × 1 mm) using sterile scissors. Genomic DNA was extracted using the commercial QIAamp DNA Mini Kit (catalog No. 51306; Qiagen), according to the dried blood spot protocol. The extracted DNA was stored at −20°C before use. For HPV DNA detection, 2 rounds of polymerase chain reaction (PCR) were performed using the same set of My11 and My09 primers (Table 1) . Those primers were targeted at the conserved L1 region of the HPV genome, which allowed the detection of a broad range of HPV types.
The procedures were performed as described elsewhere [13] . For TAP gene polymorphisms, 2 single-nucleotide polymorphisms (SNPs) in TAP1 gene (I333V and D637G) were genotyped using a PCR-restriction fragment length polymorphism technique with 2 pairs of primers ( Table 1 ). The amplified TAP1 gene fragments for I333V and D637G SNP detection were digested by BclI and AccI restriction enzymes (New England Biolabs), respectively, and 3 genotypes, interpreted as AA (wild type), AG (1 allele showed SNP), or GG (2 alleles showed SNP), were detected at each polymorphic site. Reactions were performed in duplicate with confirmation of HPV types by DNA sequencing.
Questionnaire
To evaluate women's willingness to provide MB samples, questionnaires with a total of 10 questions (Supplementary Data) were delivered to 5000 women with different backgrounds ( Figure 1A -D).
Statistical Analysis
Fisher exact tests were used to examine the association between the distribution of genotypes or alleles for TAP1 I333V and TAP1 D637G gene polymorphisms and HGCIN risk (GraphPad Prism software; version 4.0; GraphPad). Differences were considered statistically significant at P < .05.
Ethical Approval, Consent, and Permissions
The study was approved by the Clinical Research Ethics Committee, Queen Elizabeth Hospital, Hong Kong Special Administrative Region. Written consent was obtained from all participants on carrying out this study.
RESULTS
HPV DNA was detected in 83% of patients (220 of 265), 24% (28 of 118) patients who underwent a loop electrosurgical excision procedure , 0% (0 of 76) with proven recovery, and 4% of ANSs (6 of 137) ( Figure 2 ). The prevalence of HPV types (total = 226) detected in positive subjects before treatment is shown in Tables 2-4 , can be summarized as follows: (1) 3 genotypes (AA, AG, and GG) at each polymorphic site were detected in our patient cohort (Table 2) , (2) the risk of developing HGCIN was significantly reduced for AG and GG genotypes compared with the AA genotype for both polymorphisms (Table 4) , and (3) the risk of developing HGCIN was significantly reduced for carriers with a G allele compared with those with an A allele for both polymorphisms (Tables 3 and 4) .
Based on the responses from 5000 participants, the results were summarized as follows. First, 74% of participants (3700 of 5000) had undergone a Pap test before, and 26% (1300 of 5000) had not. Second, 68% (2516 of 3700) of those who had undergone a Pap test felt uncomfortable during cervical cell collection, due to pain and embarrassment; on the other hand, 32% (1184 of 3700) did not feel uncomfortable during cervical cell collection. Third, 72% of participants (3600 of 5000) said that cervical cell collection with a cytobrush for the Pap test needed to be improved. Among the 3700 who had undergone a Pap test, 92% (3404 of 3700) stated that cytobrush cervical cell collection should to be improved and urged a decrease in both invasiveness and embarrassment. However, 28% of participants (1400 of 5000) thought that no such improvement was necessary. A fourth finding was that 87% of participants (4350 of 5000) would consider using MB samples collected in a napkin for HPV detection. The remaining 13% (650 of 5000) did not support this practice because they worried about hygienic problems during storage or mailing. Fifth, 98% of participants (4900 of 5000) stated that the advantages of using MB samples for HPV detection were no pain, no embarrassment, and saving time. However, 2% (100 of 5000) felt that there was no advantage to using MB samples for this test. Finally, 44% of participants (2200 of 5000) felt uncomfortable delivering or mailing the MB sample to the laboratory. Among them, 100% of them were worried about hygienic problem and 6% were worried about confidentiality and embarrassment if the mailing was lost. Alternatively, 56% (2800 of 5000) reported not feeling uncomfortable.
DISCUSSION
Statement of Principle Findings
In this study, we have achieved significant results using MB as a noninvasive approach: (1) HPV DNA was detected in patients with CIN and HPV infection and their types were identified; (2) 2 ANSs with HR HPV and 1 with LR HPV had CIN1 and HPV infection diagnosed, respectively; (3) TAP1 I333V and TAP1 D637G gene polymorphisms were detected, and the risk of HGCIN was reduced for genotypes AG and GG and carriers with a G allele; and (4) in general, women accepted the use of MB samples for HPV detection but worried about hygienic problem during storage or mailing.
Strengths and Weaknesses of the Study
MB samples provide a rich and a stable source of materials for CC screening. Moreover, collecting MB in a napkin is completely noninvasive, without any discomfort or pain for the participants. To our knowledge, this is the first and the largest study not only to use MB samples to detect HPV DNA and TAP1 gene polymorphisms but also to explore whether women would accept the use of MB samples collected in a napkin for HPV detection.
HPV was successfully detected and typed in 83% of patients but not in 76% of those receiving treatment and 100% of those with proved recovery justifies long-term follow-up to prevent relapse in patients with HR HPV. Moreover, the discovery of MB HPV DNA in 6 ANSs, 3 with CIN1 or HPV infection, proves that this noninvasive test has high potential for screening premalignant cervical changes. HPV typing by DNA sequencing after HPV DNA detection with PCR has important advantages compared with PCR HPV DNA detection alone: it enables us to know whether HPV detected after PCR belongs to the LR or HR type, so patients with HR HPV may be stratified to undergo a Pap test and such that the specificity of the MB HPV DNA test can be increase, and it can rule out any false-positive result after PCR. Therefore, our work has important clinical applications in 3 scenarios: (1) routine screening for women, especially in low-resource countries where the necessary infrastructures are not available [18, 19] ; (2) routine screening for women who are reluctant to consult physicians owing to embarrassment or pain even when symptoms appear; and (3) more frequent follow-up for treatment success or recovery than is achieved with Pap testing.
To further demonstrate that other DNA aberrations can be detected in MB samples, TAP1 gene polymorphisms detection were studied, and we are the first to show that MB TAP1 I333V and TAP1 D637G gene polymorphisms were associated with a reduced risk of HGCIN. Our work suggests a potential application to screen patients with HPV-positive MB samples for TAP1 I333V and TAP1 D637G gene polymorphisms using the same napkin samples. This strategy may lead to better utility of resources, because HPV-infected patients with genotype AG or GG may need less frequent follow-up. Based on our preliminary results, MB samples are reliable for detecting TAP1 gene polymorphisms, because our findings with these samples match those for cervicovaginal lavage samples [17] .
The responses from 5000 women were very significant, clearly delivering a message on their expectations for an improvement over Pap test cervical cell collection. The use of MB samples for HPV detection meets their expectations; a majority of participants agreed to use MB samples owing to the definite advantages of no pain, no embarrassment, and time savings. However, 32% of participants who had undergone Pap testing did not feel uncomfortable during cervical cell collection, possibly because they were >35 years old with experience of multiple Pap tests (≥10) and were already accustomed to this collection method. 
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Abbreviations: HGCIN, high-grade cervical intraepithelial neoplasia; HPV, human papillomavirus; LGCIN, low-grade cervical intraepithelial neoplasia. Furthermore, nearly half of the participants worried about the hygienic conditions during storage or mailing of the MB sample. Special waterproof and heat-resistant bags for transporting MB samples to designated collection centers may need to be considered. The main advantages of use MB samples for DNA detection, compared with other biological fluids, are that it is not necessary to store the napkin samples at a particular temperature or to centrifuge them at a particular force and speed. The samples were held in the laboratory for up to 1 year after collection. The DNA extraction began 1-7 days after collection. Dried-blood protocols were used for DNA extraction. In fact, we have analyzed a small cohort of 20 napkin samples and performed the DNA extraction and the downstream experiment for each sample at multiple time points, at 1 day, 7 days, and 1, 3, 6, and 12 months. Results were found to be the same. Therefore, sensitivity and specificity are not affected by the receiving time and any subsequent delay.
The main reason for this success is that the napkin samples are kept in cabinets in the dark and at room temperature (about 21°C-23°C) (data not shown). Moreover, the size of the napkin cut for DNA extraction is very small, so the rest of the napkin can be used for other purposes. Although the focus of research in this study has the undeniable merit of offering valuable insights into the development of MB samples for SIL detection, the study has several important limitations. First, a long-term follow-up period to examine the prognostic value of MB HPV DNA and the HGCIN predictive value of MB TAP1 I333V and D637G gene polymorphisms in patients with low-grade CIN or HPV infection was not available. Second, the sample size for ANSs was not large enough, because only 2% of ANSs with normal cytological findings had MB HPV DNA, compared with 11% of ANSs with HPV DNA in Hong Kong in 2002 [20] . Despite this, our findings may reflect significant improvement after implementation of the cervical screening program in 2004 and the HPV vaccination program in 2007 [21, 22] .
Strengths and Weaknesses in Relation to Other Studies
We are the first group to use MB samples to test for HPV DNA and TAP1 I333V and TAP1 D637G gene polymorphisms in patients with CIN or HPV infection. To our knowledge, Tong et al [23] used vaginal discharge samples collected on napkins to detect HPV DNA in 100% of patients (17 of 17) with CIN or HPV infections. Comparing HPV DNA detection between MB and vaginal discharge samples, MB samples have an absolute advantage, because they can be collected monthly in women before menopause, whereas vaginal discharge is not a biological fluid for regular sample collection. Furthermore, our investigation into the utility of MB HPV DNA is more extensive with a much larger sample size, so the results should be more representative and reliable. Finally, there is no question that we are the first to gather and analyze the responses from 5000 women on their willingness to use MB samples for HPV detection, and the positive feedback is encouraging, implying that this testing method has the potential to be developed for population screening.
Implications for Clinicians and Policymakers
Our findings of high sensitivity, specificity, and positive predictive value for HPV DNA in SIL detection have direct implications for the use of MB samples in screening women for disease. Moreover, the positive responses from 5000 women should encourage cytopathologists and hospital administrators to explore the logistics of using MB HPV DNA as an adjunctive test to the conventional Pap test for SIL detection, so that more women, especially sex workers and those in low-resource countries, will participate in the cervical screening program with no increase in cost.
Unanswered Questions and Future Research
Currently, a multicenter study for MB HPV DNA and TAP1 gene polymorphisms detection is in progress so our results can be validated. Moreover, a long-term follow-up study will be carried out to examine the prognosis of MB TAP1 I333V and D637G genotypes in the same cohort of patients with low-grade CIN or HPV infection. Finally, we will also investigate the measurement of HPV DNA concentrations with quantitative PCR to determine whether HPV DNA load can reflect the severity of CIN or HPV infection.
Conclusions
Our findings not only demonstrate that a new era of noninvasive detection for HPV and SNP has become a reality, but they also open up the exciting possibility of using MB samples to detect other sexually transmitted diseases and DNA aberrations, such as mutation, methylation, or loss of heterozygosity in women with diseases. We strongly hope that a noninvasive MB HPV DNA with higher sensitivity and specificity than conventional Pap tests can be developed, enabling new algorithms for screening, including triage of patients with HR HPV DNA for Pap test and colposcopy, with the ultimate aim of reducing the incidence of CC with a cost-effective and readily available test.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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